IP Library Granted Patent US 11,344,636
Granted Patent B2
US 11,344,636 · App. 15/889,429 · Granted May 31, 2022

Methods for making ultrasound contrast agents

Inventors: Simon P. Robinson (Stow, MA); Robert W. Siegler (Chelmsford, MA); Nhung Tuyet Nguyen (Westford, MA); David C. Onthank (Groton, MA); Tarakeshwar Vishwanath Anklekar (Billerica, MA); Charles Chester Van Kirk (Beverly, MA)
Assignee: Lantheus Medical Imaging, Inc.
A61K49/223A61B8/481A61K49/226A61K49/227C07F9/09C07F9/106
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,344,636
App. No.
15/889,429
Granted
May 31, 2022
Kind
B2
Abstract

Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

Claims (10)

1. A method for preparing a phospholipid suspension useful for preparing lipid-encapsulated gas microspheres comprising

combining one or more phospholipids and a non-aqueous solvent, in a methanol and toluene free and methyl t-butyl ether free condition, to form a phospholipid solution having calcium and/or magnesium divalent metal cation present at a total divalent metal cation concentration of less than 0.7 ppm, and

combining the phospholipid solution with an aqueous solution to form a phospholipid suspension.

2. The method of claim 1 , wherein the one or more phospholipids comprise (a) DPPC and MPEG-5000-DPPE or (b) DPPA, DPPC and MPEG-5000-DPPE.

3. The method of claim 2 , wherein DPPA has a combined calcium and magnesium concentration of less than 780 ppm, DPPC has a combined calcium and magnesium concentration of less than 90 ppm, and MPEG5000-DPPE has a combined calcium and magnesium concentration of less than 115 ppm.

4. The method of claim 1 , wherein the non-aqueous solvent comprises propylene glycol.

5. The method of claim 1 , wherein the non-aqueous solvent has a combined calcium and magnesium concentration of less than 0.7 ppm.

6. The method of claim 1 , wherein the phospholipid solution has no detectable phospholipid precipitate.

7. The method of claim 1 , wherein the one or more phospholipids comprise DPPA, DPPC and MPEG-5000-DPPE in a mole % ratio of 10 to 82 to 8 (10:82:8).

8. The method of claim 1 , wherein the non-aqueous solvent comprises propylene glycol and glycerol.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Dec 2, 2022
From: WELLS FARGO BANK, N.A.
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 062047/0925 →
SECURITY INTEREST Recorded Dec 2, 2022
From: LANTHEUS MEDICAL IMAGING, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC; PROGENICS PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 062047/0960 →
SECURITY AGREEMENT Recorded Jun 28, 2019
From: LANTHEUS MEDICAL IMAGING, INC.
To: WELLS FARGO BANK, N.A.
Reel/Frame 049628/0001 →
CONFIRMATORY ASSIGNMENT Recorded Mar 2, 2018
From: ROBINSON, SIMON P.; SIEGLER, ROBERT W.; NGUYEN, NHUNG TUYET; ONTHANK, DAVID C.; VAN KIRK, CHARLES CHESTER; ANKLEKAR, TARAKESHWAR VISHWANATH
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 045484/0557 →
Continuity (4)
Continuation 15602580 · May 23, 2017
Division 15461469 · Mar 16, 2017
Provisional Application 62359181 · Jul 6, 2016
Related Publication 20190142978A1 · May 16, 2019
Cited By (1)
US 12,296,029